Our March 8, 2016 podium presentation at Molecular Medicine Tri-conference highlights how tumor genomic profiling can direct patients to new therapeutic possibilities.
Victor Weigman, Ph.D., Director, Translational Genomics, Q2 Solutions
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.